Why Amyloidosis Is Often Missed in Africa and How Awareness Can Save Lives

1. Symptoms Mimic Common Diseases

One of the major challenges in diagnosing amyloidosis is that its symptoms often resemble more common conditions.

For example:

• Heart involvement may appear similar to hypertensive heart disease or heart failure.

• Kidney involvement may resemble diabetic nephropathy.

• Neurological symptoms may be mistaken for peripheral neuropathy caused by diabetes or infections.

Because these conditions are far more common in clinical practice, amyloidosis may not initially be considered.

2. Limited Awareness Among Healthcare Providers

Amyloidosis remains unfamiliar to many clinicians, particularly in regions where formal training on rare diseases is limited. In medical education programs across many African countries, amyloidosis receives little attention compared to infectious diseases or more prevalent chronic illnesses.

As a result, healthcare providers may not recognize the warning signs or may not know when to suspect amyloidosis in patients with unexplained organ dysfunction.

3. Restricted Access to Specialized Diagnostic Tests

Diagnosing amyloidosis requires specific laboratory and imaging tests that are not always readily available.

Key diagnostic tools include:

• Serum free light chain assays

• Immunofixation electrophoresis

• Bone scintigraphy imaging

• Tissue biopsy with amyloid typing

• Advanced cardiac imaging, such as echocardiography or cardiac MRI

In many healthcare settings across Africa, these tests may be unavailable or limited to specialized centers in major cities.

Without these tools, confirming the diagnosis becomes difficult.

4. Overlap With High-Burden Diseases

Africa faces a significant burden of infectious and chronic diseases, including HIV, tuberculosis, hypertension, and diabetes. Healthcare systems are often focused on managing these widespread conditions.

When patients present with symptoms such as fatigue, heart failure, or kidney disease, clinicians naturally prioritize these more common diagnoses. Amyloidosis may therefore remain hidden behind more familiar conditions.

5. Lack of Epidemiological Data

Another challenge is the scarcity of reliable data on amyloidosis in African populations. Without registries or large-scale studies, it is difficult to estimate how many people are affected.

This lack of data contributes to the misconception that amyloidosis is extremely rare in Africa. In reality, it may simply be underrecognized and underreported.